Renol Polychem Limited IPO Review
Neutral100-100 · SME
✦
Analyst Verdict
Renol Polychem Limited IPO
Neutral
IPO at a Glance
Price Band
100-100
Issue Size
25cr
Opens
2025-07-29
Closes
2025-08-02
Listing
2025-08-05
Category
SME
Key Strengths
✓Diverse product portfolio catering to wide range of customers
✓Long-standing client and supplier relationships
✓Established manufacturing facility and In-House R&D capabilities
✓Customised solutions for niche applications
✓Promoters with significant industry experience
Key Risks
⚠High reliance on Gujarat, Tamilnadu and Karnataka, accounting for over 95% of revenue(FY24), makes the business vulnerable to regional disruptions
⚠Dependence on few customers & suppliers without contracts may disrupt operations
⚠Loss of rented premises, including manufacturing facility, registered office and warehouses, may impact operations and increase costs
⚠Competitive market and regulatory challenges, non-compliance could affect business performance
Frequently Asked Questions
Should I apply for Renol Polychem Limited IPO?
Based on our analysis, our rating for Renol Polychem Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Renol Polychem Limited IPO?
High reliance on Gujarat, Tamilnadu and Karnataka, accounting for over 95% of revenue(FY24), makes the business vulnerable to regional disruptions Dependence on few customers & suppliers without contracts may disrupt operations Loss of rented premises, including manufacturing facility, registered office and warehouses, may impact operations and increase costs
What are the strengths of Renol Polychem Limited IPO?
Diverse product portfolio catering to wide range of customers Long-standing client and supplier relationships Established manufacturing facility and In-House R&D capabilities
What is the price band of Renol Polychem Limited IPO?
The price band for Renol Polychem Limited IPO is 100-100. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more